Skip to main content
Search
Main content
David Klenerman

Prof Sir David Klenerman

(FMedSci FRS)

Group Leader

Determining how protein clumps form, damage the brain and change as the different neurodegenerative diseases develop to know which ones to target for therapies

Techniques

Advanced microscopy & imaging, Biophysical techniques, Fluid biomarkers, Software development

Biography

Professor Sir David Klenerman is a physical chemist who graduated and completed his doctorate at Cambridge University working with Professor Ian Smith on infra-red chemiluminescence for his PhD in 1985. This was followed by postdoctoral research at Stanford University, California with Professor Dick Zare on high overtone chemistry. He then returned to the UK and worked for seven years for BP Research in their Laser Spectroscopy Group before returning to the Department of Chemistry, University of Cambridge, progressing to a Professorship. At Cambridge his work has focussed on the development and application of physical methods, particularly laser spectroscopy and single molecule fluorescence, to biological and biomedical problems.  

His recognition includes being knighted by the Queen in 2018, for development of high speed DNA sequencing, and being awarded the Royal Society’s Royal Medal in 2018. He was awarded the 2020 Millennium Technology Prize jointly with Shankar Balasubramanian and the 2022 Breakthrough Prize for Life Sciences and 2024 Gairdner Prize for Life Sciences jointly with Shankar Balasubramanian and Pascal Mayer for next generation DNA  sequencing.

News

- Research

New clue in understanding increased Alzheimer’s risk

Research from the University of Sheffield’s Institute of Translational Neuroscience (SITraN), together with scientists from...

Learn more New clue in understanding increased Alzheimer’s risk

Key publications

Communications medicine
Published
Detection of p53 aggregates in plasma of glioma patients
Authors
Yunzhao Wu, Jeff Y L Lam, Matthaios Pitoulias, Dorothea Böken, Ziwei Zhang, Renuka Chintapalli, Emre Fertan, Zengjie Xia, John S H Danial, Gemma Tsang-Pells, Emily Fysh, Linda Julian, Kevin M Brindle, Richard Mair, David Klenerman
Detection of p53 aggregates in plasma of glioma patients
Alzheimer's & dementia : the journal of the Alzheimer's Association
Published
Lecanemab preferentially binds to smaller aggregates present at early Alzheimer's disease
Authors
Emre Fertan, Jeff Y L Lam, Giulia Albertini, Maarten Dewilde, Yunzhao Wu, Oluwatomi E S Akingbade, Dorothea Böken, Elizabeth A English, Bart De Strooper, David Klenerman
Lecanemab preferentially binds to smaller aggregates present at early Alzheimer's disease

Klenerman Lab

Explore the work of the Klenerman Lab focused on determining how protein clumps form, damage the brain and change as the different neurodegenerative diseases develop to know which ones to target for therapies.

Klenerman culture